Course Information

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC and Tumor Board Tuesday.

DISCLOSURE OF COMMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Merck Sharp & Dohme LLC. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

MODERATOR

Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

SCHEDULE

#TumorBoardTuesday takes place on Tuesdays at 8:00 PM Eastern Time.

Date	Topic	Faculty	Disclosures
Tuesday, December 9, 2025	ADCs for Metastatic NSCLC: T-DXd & Teliso-V	Aakash Desai, MBBS, MPH Assistant Professor of Medicine O'Neal Cancer Center University of Alabama Birmingham, Alabama Sanad Alhushki, MD Research Fellow O'Neal Cancer Center University of Alabama Birmingham, Alabama	Aakash Desai, MBBS, MPH Advisory Board/Consulting: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, ConcertAI, Daiichi Sankyo, Foundation Medicine, Janssen Oncology, Lilly, Merus, Regeneron, Sanofi Sanad Alhushki, MD does not have any financial relationships or relationships to products or devices with ineligible companies.
Tuesday, November 11, 2025	New Targets in 2L ES-SCLC AMA credit	Estelamari Rodriguez, MD, MPH Clinical Research Lead Thoracic Oncology Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine Miami, Florida Ana S. Salazar, MD Hematology-Oncology Fellow University of Miami Jackson Memorial Hospital Sylvester Comprehensive Cancer Center Miami, Florida	Estelamari Rodriguez, MD, MPH Advisor: Amgen, AstraZeneca, Genentech, Janssen, Novocure, Nuvalent, Pfizer, Regeneron These relationships have ended within the past 24 months. Ana S. Salazar, MD* does not have any financial relationships or relationships to products or devices with ineligible companies.
Tuesday, October 7, 2025	Uncommon EGFR Mutations: Targeting Exon 20 in Advanced NSCLC AMA credit	Melina Marmarelis MD, MSCE Assistant Professor Physician Lead, Airways Research Program Medical Director, Mesothelioma Program Co-Director, Molecular Tumor Board University of Pennsylvania Philadelphia, Pennsylvania Benjamin Bleiberg, MD Hematology/Oncology Fellow University of Pennsylvania Philadelphia, Pennsylvania	Melina Marmarelis MD, MSCE Consultant: Astra Zeneca, Bayer, Blueprint Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Ikena, Janssen, Neuvogen, Novocure, Regeneron, Takeda Honoraria: Thermo Fisher Researching Funding from Institution: AstraZeneca, Eli Lilly, Genentech, Merck Stock: Johnson & Johnson Benjamin Bleiberg, MD Consultant, Steering Committee Member: Janssen Honoraria: MJH Life Sciences
Tuesday, September 16, 2025	When Liquid Isn’t Enough: Optimizing Molecular Testing in NSCLC AMA credit	Bruna Pellini, MD Assistant Member, Department of Thoracic Oncology H. Lee Moffitt Cancer Center and Research Institute Assistant Professor, Department of Oncologic Sciences Morsani College of Medicine University of South Florida Tampa, Florida Hiba Narvel, MD, MBBS Fellow physician Medical College of Wisconsin Milwaukee, Wisconsin	Bruna Pellini, MD Abstract: Guardant Health Advisory Boards: AstraZeneca, Bristol Myers Squibb, Guardant Health, Illumina, Regeneron Consulting: Bayer Grant: Bristol Myers Squibb Scientific Steering Committee: Bayer, Regeneron Speaker Honoraria, Travel, and Research Grant: Merck, MSD Hiba Narvel, MD, MBBS does not have any financial relationships or relationships to products or devices with ineligible companies.
Tuesday, August 5, 2025	Frontline IO Strategies for STK11/KEAP1- Mutant mNSCLC AMA credit	Biagio Ricciuti, MD, PhD Thoracic Medical Oncologist Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts Alessandro Di Federico, MD Medical Oncologist Research Fellow Dana-Farber Cancer Institute Boston, Massachusetts	Biagio Ricciuti, MD, PhD Consultant: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Caris Life, Regeneron Speaker: AstraZeneca, Regeneron Honoraria: Society for Immunotherapy of Cancer, Targeted Oncology All of the above relationships have ended within the past 24 months. Alessandro Di Federico, MD Advisor: IQVIA, Novartis Consultant: Hanson-Wade, IQVIA, Novartis Speaker:* Hanson-Wade* Travel Support: Johnson & Johnson *These relationships have ended within the past 24 months.
Tuesday, June 17, 2025	Targeting Classical EGFR Mutations in mNSCLC AMA credit	Eric Singhi, MD Assistant Professor University of Texas MD Anderson Cancer Center Houston, Texas Kelsey Pan, MD, MPH Hematology/Oncology Fellow University of Texas MD Anderson Cancer Center Houston, Texas	Eric Singhi, MD Advisory Boards: Amgen, AstraZeneca, Bayer, Bristol Meyers Squibb, Janssen Novocure, Regeneron Kelsey Pan, MD, MPH Advisory Board: Johnson & Johnson
Tuesday, May 13, 2025	Are all EQUAL?: IO Strategies in Early NSCLC AMA credit	Narjust Florez, MD, FASCO Co-Director, Young Lung Cancer Program Thoracic Medical Oncologist, Dana-Farber Cancer Institute Assistant Professor of Medicine, Harvard Medical School Boston, Massachusetts Mihaela Aldea, MD, PhD Assistant Professor, Paris Saclay University, Paris, France Medical Oncologist, Gustave Roussy, Villejuif, France Visiting Scientist, Dana-Farber Cancer Institute Boston, Massachusetts	Narjust Florez, MD, FASCO Advisor/Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Johnson and Johnson, Merck, Mirati, Novartis, Novocure, Pfizer, Regeneron Mihaela Aldea, MD, PhD Research Funding (Institution): Amgen, AstraZeneca, Owkin

Stay tuned for upcoming conversations!

PROGRAM OVERVIEW

Oncologists and other clinicians who treat patients with lung cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of thoracic based tumors. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in lung cancer that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.

Tumor Board Tuesday is a regularly scheduled, Twitter-based case discussion forum led by expert faculty modeled on the traditional tumor board presentation. Cases are based on realistic scenarios and supporting data is included for optimal treatment selection and patient management.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists, pulmonologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in the treatment and management of patients with lung cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

Integrate genomic, immunogenic, and proteomic aberration assessments to guide treatment decisions
Select personalized therapeutic regimens consistent with current evidence and best practices
Implement supportive care strategies to mitigate and manage unique toxicities associated with recently approved and emerging therapies

Faculty Information and Disclosures

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.

The Integrity CE, LLC planners and managers and Tumor Board Tuesday patient planners do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

If you wish to claim credit for your participation in TBT conversations from April 1, 2025 – March 31, 2026, you can do so here: https://www.integrityce.com/TBTeval25

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this Other activity (a regularly scheduled social media-based tumor board) for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Tumor Board Tuesday 2025: Lung Cancers